You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the NINLARO (ixazomib citrate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR NINLARO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for NINLARO

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01415882 ↗	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	Recruiting	National Cancer Institute (NCI)	Phase 2	2012-01-31	This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01415882 ↗	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	Recruiting	Mayo Clinic	Phase 2	2012-01-31	This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01718743 ↗	Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Millennium Pharmaceuticals, Inc.	Phase 2	2012-12-03	This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
NCT01718743 ↗	Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2012-12-03	This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for NINLARO

Condition Name

Chart
Table

Condition Name for NINLARO
Intervention	Trials
Recurrent Plasma Cell Myeloma	10
Plasma Cell Myeloma	7
Multiple Myeloma	7
Refractory Plasma Cell Myeloma	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for NINLARO
Intervention	Trials
Multiple Myeloma	30
Neoplasms, Plasma Cell	28
Lymphoma	5
Lymphoma, Mantle-Cell	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for NINLARO

Trials by Country

Map
Table

Trials by Country for NINLARO
Location	Trials
United States	164
France	14
United Kingdom	9
Czechia	8
Poland	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for NINLARO
Location	Trials
Minnesota	15
California	11
Missouri	10
Georgia	9
Florida	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for NINLARO

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for NINLARO
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 2	29
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for NINLARO
Clinical Trial Phase	Trials
Active, not recruiting	21
Recruiting	15
Not yet recruiting	3
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NINLARO

Sponsor Name

Chart
Table

Sponsor Name for NINLARO
Sponsor	Trials
National Cancer Institute (NCI)	26
Takeda	12
Mayo Clinic	11
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for NINLARO
Sponsor	Trials
Other	48
Industry	37
NIH	27
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.